Litigation Details for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)

Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)

Docket		Date Filed	2018-12-10
Court	District Court, D. Delaware	Date Terminated	2019-05-09
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	EAGLE PHARMACEUTICALS, INC.
Patents	10,010,533; 9,265,831; 9,572,796; 9,572,797
Attorneys	Nathan Roger Hoeschen
Firms	Smith, Katzenstein, & Jenkins LLP
Link to Docket	External link to docket

Details for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-12-10	1	Complaint	(“the ’797 patent”); and 10,010,533 (“the ’533 patent”) (collectively, “the Patents-in-Suit”). …COUNT IV – INFRINGEMENT OF U.S. PATENT NO. 10,010,533 UNDER 35 U.S.C. § 271(e)(2) … INFRINGEMENT OF U.S. PATENT NO. 10,010,533 94. Eagle incorporates…infringement of the ’831 patent, the ’796 patent, the ’797 patent, and the ’533 patent. (b…of Eagle’s U.S. Patent Nos. 9,265,831 (“the ’831 patent”); 9,572,796 (“the ’796 patent”); 9,572,797 (“	External link to document
2019-01-10	17	Redacted Document	(“the ‘797 patent”); and 10,010,533 (“the ‘533 patent”) (collectively, the “patents-in-suit”), which …infringes U.S. Patent Nos. 9,265,831 (“the ‘831 patent”); 9,572,796 (“the ‘796 patent”); 9,572,797 (“… the patents-in-suit. Rather, Plaintiff’s complaint alleges that Slayback infringes the patents-in-suit…infringe any claim of the patents-in-suit. All of the independent claims of these patents require a pharmaceutically…equivalents to prove infringement of the patents-in-suit. “[W]hen a patent drafter discloses but declines to	External link to document
2019-02-11	23	Redacted Document	“’831 Patent”); 9,572,796 (the “’796 Patent”); 9,572,797 (the “’797 Patent”); and 10,010,533 (the “’… four patents listed in the Orange Book and covering the formulation of Belrapzo®. U.S. Patents 9,265,831…“’533 Patent”) (the “Patents-in-Suit”) list inventors Nagesh Palepu and Philip Buxton. Certain claims…Plaintiff Plausibly Pled that Slayback Infringes the Patents-in-Suit............8 3. … questions over the proper interpretation of a patent’s intrinsic record are “not suitable” and “particularly	External link to document
2019-05-09	28	Memorandum Opinion	the "#796 patent"), 9,572,797 (the "#797 patent"), and 10,010,533 (the "#533…equivalents of four patents: U.S. Patent Nos. 9,265,831 (the "#831 patent"), 9,572,796 …glycol in embodiments of the patented invention. See, e.g., #796 patent at 1:60-64, 4:34-47, 5:27-35,…;#533 patent"). See generally D.I. 1. Pending before me is Slayback's motion for judgment…manufacture and sell before the four asserted patents expire a bendamustine drug that is bioequivalent	External link to document
2019-05-09	30	Patent/Trademark Report to Commissioner	;9,572,796 B2 ;9,572,797 B2 ;10,010,533 B2. (Attachments: # 1 Order granting Motion for Judgment on the… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,265,831 B2 ;…December 2018 9 May 2019 1:18-cv-01953 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-05-09	31	Memorandum Opinion	the "#796 patent"), 9,572,797 (the "#797 patent"), and 10,010,533 (the "#533…equivalents of four patents: U.S. Patent Nos. 9,265,831 (the "#831 patent"), 9,572,796 …glycol in embodiments of the patented invention. See, e.g., #796 patent at 1 :60-64, 4:34-47, 5:27-35…;#533 patent"). See generally D.I. 1. Pending before me is Slayback's motion for judgment …manufacture and sell before the four asserted patents expire a bendamustine drug that is bioequivalent	External link to document